Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706662 | 0.93 | SELE (0.42) | SELEVCAM1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL6708399 | 0.92 | SELE (0.41) | SELEVCAM1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL6708349 | 0.91 | HPGD (0.41) | SELEVCAM1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL7098332 | 0.86 | ALDH1A1 (0.50) | SELEVCAM1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL6707044 | 0.86 | RPS6KB2 (0.38) | ALDH1A1KDM4ERPS6KB2TDP1GAA | |
| SCHEMBL6708455 | 0.85 | RPS6KB2 (0.37) | ALDH1A1KDM4EMEN1KMT2ARPS6KB2 | |
| SCHEMBL7183160 | 0.82 | PDE5A (0.41) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL7102424 | 0.81 | ALDH1A1 (0.47) | SELEVCAM1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL7096431 | 0.80 | KDM4E (0.46) | SELEVCAM1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL6708286 | 0.79 | KAT2B (0.40) | ALDH1A1RPS6KB2HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040072846-A1 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040034040-A1 | Use of thienopyrimidines | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| US-6495554-B2 | PHOSPHODIESTERASE V INHIBITORS, TREATING CARDIOVASCULAR DISORDERS, AND THERAPY OF ERECTILE DYSFUNCTION. | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-12-17 | — | — | US | disclosed |
| US-20020132818-A1 | Thienopyrimidines | MERCK PATENT GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-6420368-B1 | DISEASES OF THE CARDIOVASCULAR SYSTEM AND FOR TREATMENT AND/OR THERAPY OF ERECTILE DYSFUNCTION. | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | SELE 4109/4885VCAM1 1838/4885ALDH1A1 1785/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | SELE 1192/4885VCAM1 1309/4885ALDH1A1 3483/4885 |
| US-20040034040-A1 | Use of thienopyrimidines | DPYD, TBXAS1, TYMS | SELE 3702/4885VCAM1 1181/4885ALDH1A1 497/4885 |
| US-20020132818-A1 | Thienopyrimidines | PDE5A, PDE3B, PDE3A | SELE 1533/4885VCAM1 1213/4885ALDH1A1 313/4885 |
| US-20040072846-A1 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives | PTGER1, TBXA2R, PTGIS | SELE 4284/4885VCAM1 1154/4885ALDH1A1 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.